Funds and ETFs Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 23:00:00 23/06/2024 BST 5-day change 1st Jan Change
179,000 KRW +1.07% Intraday chart for Celltrion, Inc. -2.40% -11.17%

ETFs positioned on Celltrion, Inc.

Name Weight AuM 1st Jan change Investor Rating
4.14% 2 M€ -14.14%
0.99% 11 M€ -.--% -
0.53% 15 M€ +18.95%
0.18% 2,838 M€ +11.49% -
0.18% 152 M€ +7.98% -
0.18% 451 M€ +8.61% -
0.15% 4 M€ -4.41% -
0.06% 11 M€ +6.30%
0.05% 7 M€ +4.07% -
0.05% 114 M€ +5.58% -
0.04% 1 M€ +3.49% -
0.04% 3 M€ -.--% -
0.04% 0 M€ 0.00% -
0.02% 36 M€ +10.48% -
0.02% 324 M€ +8.38% -
0.02% 40 M€ +6.99% -
0.02% 414 M€ +11.77% -
0.01% 104 M€ +5.49% -
0.01% 17 M€ +3.51% -
0.01% 55 M€ +2.08% -
0.01% 8 M€ +0.46% -
0.00% 7 M€ +0.11% -
0.00% 32 M€ +4.88% -
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
179,000 KRW
Average target price
231,375 KRW
Spread / Average Target
+29.26%
Consensus
  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. Funds and ETFs Celltrion, Inc.